MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/circep.119.007545

Медицинская библиотека · Circulation. Arrhythmia and electrophysiology · 2019

Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2.

Essebag Vidal, Healey Jeff S, Joza Jacqueline, Nery Pablo B, Kalfon Eli, Leiria Tiago L L, Verma Atul, Ayala-Paredes Felix, Coutu Benoit, Sumner Glen L, Becker Giuliano, Philippon François, Eikelboom John, Sandhu Roopinder K, Sapp John, Leather Richard, Yung Derek, Thibault Bernard, Simpson Christopher S, Ahmad Kamran, Toal Satish, Sturmer Marcio, Kavanagh Katherine, Crystal Eugene, Wells George A, Krahn Andrew D, Birnie David H

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Oral anticoagulant use is common among patients undergoing pacemaker or defibrillator surgery. BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial; NCT00800137) demonstrated that perioperative warfarin continuation reduced clinically significant hematomas (CSH) by 80% compared with heparin bridging (3.5% versus 16%). BRUISE-CONTROL-2 (NCT01675076) observed a similarly low risk of CSH when comparing continued versus interrupted direct oral anticoagulant (2.1% in both groups). Using patient level data from both trials, the current study aims to: (1) evaluate the effect of concomitant antiplatelet therapy on CSH, and (2) understand the relative risk of CSH in patients treated with direct oral anticoagulant versus continued warfarin.

METHODS

We analyzed 1343 patients included in BRUISE-CONTROL-1 and BRUISE-CONTROL-2. The primary outcome for both trials was CSH. There were 408 patients identified as having continued either a single or dual antiplatelet agent at the time of device surgery.

RESULTS

Antiplatelet use (versus nonuse) was associated with CSH in 9.8% versus 4.3% of patients (P<0.001), and remained a strong independent predictor after multivariable adjustment (odds ratio, 1.965; 95% CI, 1.202-3.213; P=0.0071). In multivariable analysis, adjusting for antiplatelet use, there was no significant difference in CSH observed between direct oral anticoagulant use compared with continued warfarin (odds ratio, 0.858; 95% CI, 0.375-1.963; P=0.717).

CONCLUSIONS

Concomitant antiplatelet therapy doubled the risk of CSH during device surgery. No difference in CSH was found between direct oral anticoagulant versus continued warfarin. In anticoagulated patients undergoing elective or semi-urgent device surgery, the patient specific benefit/risk of holding an antiplatelet should be carefully considered.

CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT00800137, NCT01675076.

Для цитирования: Essebag Vidal, Healey Jeff S, Joza Jacqueline, Nery Pablo B, Kalfon Eli, Leiria Tiago L L, Verma Atul, Ayala-Paredes Felix, Coutu Benoit, Sumner Glen L, Becker Giuliano, Philippon François, Eikelboom John, Sandhu Roopinder K, Sapp John, Leather Richard, Yung Derek, Thibault Bernard, Simpson Christopher S, Ahmad Kamran, Toal Satish, Sturmer Marcio, Kavanagh Katherine, Crystal Eugene, Wells George A, Krahn Andrew D, Birnie David H. Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2.. Circulation. Arrhythmia and electrophysiology. 2019. DOI: 10.1161/circep.119.007545.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.